Islet Allotransplantation in Type 1 Diabetes

Paused · Phase 1

Conditions studied: Type 1 Diabetes

In brief

Islet transplantation can provide physiologic insulin replacement to patients with type 1 diabetes without the complications associated with whole pancreas transplantation. The purpose of this study is to achieve insulin-independence in patients with type 1 diabetes, thereby eliminating the need for exogenous insulin injections to maintain normal glucose levels, ameliorating severe hypoglycemia and potentially decreasing the development of diabetes-related complications. This study will investigate islet transplantation in subjects who have preserved renal function and subjects who have undergone cadaveric renal transplantation, since the latter subjects are already on immunosuppression. This is a single center, prospective trial of islet transplantation in subjects receiving islets alone or islets after kidney transplant. This is a phase I study investigating the use of islet transplantation for the treatment of type 1 diabetes. Subjects will be eligible for an islet transplant if they meet all of the inclusion criteria and none of the exclusion criteria outlined in the protocol. In brief, the aims of this study are to establish an islet transplant program at the Ohio State University, determine the safety of islet transplantation in islet alone and kidney transplant recipients, determine whether islet transplantation will reduce the frequency of severe hypoglycemic events, determine whether a novel steroid-free immunosuppressive protocol will prevent rejection in islet transplants and to achieve insulin independence at one year after the final islet transplant.

Key facts

Study ID

NCT01705899

Run by

Ohio State University

People needed

20

Starts

2006-11-01

Expected to finish

2033-10-01

Last updated by the study team

2025-01-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 1 diabetes > 5 years
• First islet transplant
• Demonstrate intensive efforts to manage diabetes for last 6 months (≥4 SMBG/day, ≥3 injections of insulin/day or use of pump and ≥3 contacts with diabetes care team in last 12 months)
• Metabolic complications: at least one of the following:
• Reduced hypoglycemia awareness (inability to sense hypoglycemia until blood glucose falls to < 54 mg/dl or > one hypoglycemic episode in last 12 months requiring outside help and not explained by clear precipitant)
• ≥2 severe hypoglycemic events or ≥2 hospitalizations for diabetic ketoacidosis (DKA) in last year.
• Ability to provide written informed consent
• Age 18-65
• Specific for group 2: All of above (1-6) with renal transplant at least 6 months previous

You may not qualify if…

• Age < 18 years or > 65 years
• Inability to provide informed consent
• Body Mass Index > 29 kg/m2
• Insulin requirement of > 50 units/day
• Stimulated C-peptide ≥ 0.2 ng/ml
• Current panel reactive anti-HLA antibodies >20%
• Cardiovascular instability
• Previous islet transplant
• History of malignancy except squamous and basal cell skin cancer unless disease-free for > 2 years determined by independent oncologist
• Active peptic ulcer disease
• Condition that may interfere with absorption of medications
• Hemoglobin A1C > 12%
• Invasive aspergillus infection within one year
• Varicella titer index <1.0
• Rubella titer <10 IU/ml
• Psychiatric disorder
• Untreated hyperlipidemia: fasting total cholesterol >240 mg/dl, low density lipoprotein>130 mg/dl, or triglycerides >200 mg/dl
• Hemoglobin <10 g/dl for females, and <11 g/dl for males, white blood cell count < 3,000/µL, platelet count of <150,000/microliter, CD4+ count <500/microliter
• Liver function test abnormalities (if any value > 1.5 times normal, candidate will be excluded. If 1-1.5 times normal, test will be repeated. If re-test value remains above normal, candidate will be excluded).
• Prostate specific antigen >4.0 ng/ml
• Presence of gallstones, liver hemangioma, cirrhosis or evidence of portal hypertension
• Untreated proliferative diabetic retinopathy
• Females: positive pregnancy test, intent for future pregnancy, or any subject of reproductive age who is not surgically sterile and is unable or unwilling to use acceptable method of contraception
• Female subjects who are breast-feeding
• Adrenal insufficiency: 8am cortisol >19 mcg/dl adequate. Values 19 mcg/dl will be followed by Adreno-Corticotropic Hormone stimulation test

Where it is running

• The Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.